RhumbLine Advisers’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.1M | Buy |
71,058
+1,130
| +2% | +$49.3K | ﹤0.01% | 1654 |
|
|
2025
Q1 | $1.91M | Buy |
69,928
+5,771
| +9% | +$158K | ﹤0.01% | 1827 |
|
|
2024
Q4 | $2.58M | Buy |
64,157
+1,861
| +3% | +$74.9K | ﹤0.01% | 1748 |
|
|
2024
Q3 | $2.95M | Sell |
62,296
-2,239
| -3% | -$106K | ﹤0.01% | 1688 |
|
|
2024
Q2 | $1.93M | Buy |
64,535
+7,143
| +12% | +$213K | ﹤0.01% | 1908 |
|
|
2024
Q1 | $2.31M | Buy |
57,392
+3,889
| +7% | +$156K | ﹤0.01% | 1837 |
|
|
2023
Q4 | $1.36M | Sell |
53,503
-124
| -0.2% | -$3.16K | ﹤0.01% | 2102 |
|
|
2023
Q3 | $745K | Sell |
53,627
-17
| -0% | -$236 | ﹤0.01% | 2370 |
|
|
2023
Q2 | $1.23M | Sell |
53,644
-10,283
| -16% | -$236K | ﹤0.01% | 2179 |
|
|
2023
Q1 | $1.89M | Buy |
63,927
+2,707
| +4% | +$80.2K | ﹤0.01% | 1835 |
|
|
2022
Q4 | $1.53M | Buy |
61,220
+993
| +2% | +$24.8K | ﹤0.01% | 1927 |
|
|
2022
Q3 | $1.31M | Buy |
60,227
+5,339
| +10% | +$116K | ﹤0.01% | 1999 |
|
|
2022
Q2 | $1.08M | Buy |
54,888
+18,680
| +52% | +$368K | ﹤0.01% | 2102 |
|
|
2022
Q1 | $1.53M | Buy |
36,208
+2,481
| +7% | +$105K | ﹤0.01% | 1937 |
|
|
2021
Q4 | $2.14M | Buy |
33,727
+474
| +1% | +$30.1K | ﹤0.01% | 1841 |
|
|
2021
Q3 | $1.95M | Buy |
33,253
+5,696
| +21% | +$335K | ﹤0.01% | 1919 |
|
|
2021
Q2 | $1.34M | Buy |
27,557
+16,141
| +141% | +$783K | ﹤0.01% | 2121 |
|
|
2021
Q1 | $444K | Buy |
11,416
+925
| +9% | +$36K | ﹤0.01% | 2546 |
|
|
2020
Q4 | $650K | Buy |
+10,491
| New | +$650K | ﹤0.01% | 2328 |
|